Compare · ALHC vs NTRA
ALHC vs NTRA
Side-by-side comparison of Alignment Healthcare Inc. (ALHC) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALHC and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $48.53B, about 17.2x ALHC ($2.82B).
- Over the past year, ALHC is down 13.2% and NTRA is up 103.2% - NTRA leads by 116.4 points.
- NTRA has been more active in the news (16 items in the past 4 weeks vs 5 for ALHC).
- Both have 25 recent analyst ratings on file.
- Company
- Alignment Healthcare Inc.
- Natera Inc.
- Price
- -
- -
- Market cap
- $2.82B
- $48.53B
- 1M return
- -27.14%
- +30.40%
- 1Y return
- -13.21%
- +103.19%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2015
- News (4w)
- 5
- 16
- Recent ratings
- 25
- 25
Alignment Healthcare Inc.
Alignment Healthcare, Inc. provides a consumer-centric platform that delivers customized health care to seniors in the United States. It offers medicare advantage plans and health plan options to its partners and patients with customized care and service; and preferred provider organization offerings. The company was founded in 2013 and is based in Orange, California.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest ALHC
- Alignment Healthcare to Present in Baird 2026 Global Healthcare Conference and Attend Morgan Stanley 24th Annual Global Healthcare Conference
- President Maroney Dawn Christine sold $70,000 worth of shares (5,000 units at $14.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.54% to 917,313 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Alignment Healthcare Inc.
- Chief Executive Officer Kao John E sold $4,136,776 worth of shares (298,000 units at $13.88) as part of a pre-agreed trading plan (SEC Form 4)
- Alignment Healthcare downgraded by Raymond James with a new price target
- SEC Form 10-Q filed by Alignment Healthcare Inc.
- Alignment Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics
- President Maroney Dawn Christine exercised 152,068 shares at a strike of $9.06 and sold $3,687,990 worth of shares (177,068 units at $20.83) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 922,313 units (SEC Form 4)
- Chief Executive Officer Kao John E sold $5,919,361 worth of shares (298,000 units at $19.86) as part of a pre-agreed trading plan (SEC Form 4)
Latest NTRA
- CO-FOUNDER Sheena Jonathan sold $1,951,942 worth of shares (6,000 units at $325.32) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 230,464 units (SEC Form 4)
- Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
- CO-FOUNDER Sheena Jonathan sold $2,888,325 worth of shares (9,150 units at $315.66) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 236,464 units (SEC Form 4)
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $641,800 worth of shares (2,000 units at $320.90) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Natera Inc.
- SEC Form 10-Q filed by Natera Inc.
- Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Natera Reports Second Quarter 2026 Financial Results
- PRESIDENT, CHIEF BUS. OFFICER Fesko John sold $79,057 worth of shares (295 units at $267.99) as part of a pre-agreed trading plan, decreasing direct ownership by 0.16% to 183,774 units (SEC Form 4) (for tax liability)
- CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold $216,030 worth of shares (795 units at $271.74) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 51,637 units (SEC Form 4) (withholding obligation)